Christoper Mutz
About Christoper Mutz
Christopher Mutz is the Head of Rare Disease with extensive experience in the pharmaceutical industry, having held significant roles at Alexion Pharmaceuticals and Merck and Co.
Head of Rare Disease Christopher Mutz
Christopher Mutz is currently the Head of Rare Disease. He has a substantial background in managing and leading business units in the pharmaceutical industry, particularly in the area of rare diseases. His role encompasses overseeing the strategy and operations aimed at addressing unmet needs in the rare disease space.
Christopher Mutz's Tenure at Alexion Pharmaceuticals
Christopher Mutz spent over eight years at Alexion Pharmaceuticals. He most recently served as Vice President of the U.S. Neurology Business Unit. His tenure at Alexion saw him responsible for the successful launch of Soliris for gMG (generalized myasthenia gravis) and NMOSD (neuromyelitis optica spectrum disorder) in the United States. Prior to this, he served as Vice President of the U.S. Metabolic Business Unit and National Sales Director of the U.S. Metabolic Business Unit.
Christopher Mutz's Career at Merck and Co.
Christopher Mutz worked at Merck and Co. for 11 years. During his tenure there, he held various commercial roles of increasing responsibility. This experience provided him with a broad understanding of the pharmaceutical industry and the complexities involved in commercial operations.
Christopher Mutz's Educational Background
Christopher Mutz holds a Bachelor of Arts in Biology from the University of Virginia. He furthered his education by earning a Master of Business Administration from the Johnson Graduate School of Management at Cornell University. This combination of scientific and business education has equipped him with a robust foundation for his roles in the pharmaceutical sector.